| Name | Title | Contact Details |
|---|
Welcome to FOLX, the first digital Telehealth company that gives the LGBTQIA+ community access to quality care that’s in service of our needs and in celebration of our lives.
Since 1968 our goal has been straightforward: help patients get their life back on track and achieve a life of sobriety, free from drug use and symptoms of mental illness. A life that is productive, socially responsible and healthy. Gateway Foundation is one of the nation`s largest nonprofit provider of substance use disorder treatment and a nationally recognized leader in the field of addiction medicine. With treatment programs in Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas and Wyoming we specialize in substance use disorders for patients diagnosed with substance use disorder and mental health disorders. Gateway Foundation`s professional clinicians support over 9,000 people a day to successfully complete treatment by developing a personalized plan to treat the underlying causes of substance use disorder—not just their addiction to drugs or alcohol.
Siskin Hospital was founded in 1989 as the first freestanding, not-for-profit rehabilitation hospital in Tennessee built specifically for rehabilitation patients. Currently, Siskin Hospital remains as the only not-for-profit rehabilitation hospital in Tennessee, offering an all-inclusive campus, as well as off-campus locations, dedicated to meeting a wide variety of rehabilitation needs. Siskin Hospital offers all private patient rooms and has specialized Inpatient treatment programs in brain injury, amputation, stroke, spinal cord injury, orthopedics, neurological disorders, and major multiple trauma, among other illnesses and disorders.
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches designed to enable the body`s immune system to fight disease. The company`s technologies are engineered to activate the immune system`s natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic disease. Immune Design`s clinical programs are the product of its two synergistic platforms: DCVexTM and GLAASTM.
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.